-
How a £1.5k gadget could rebuild the sex lives of prostate cancer survivors
28 Apr 2024 13:16 GMT
… No drug side-effects
It’s claimed that 4.5million drugs for … men affected by ED after prostate cancer treatment are being left with “ … have any problems taking the medication, but common side effects – … clinical trial in the US in order to get FDA approval.
-
Science & Medicine: Revolutionizing prostate cancer treatment
28 Apr 2024 12:19 GMT
… questions like, "does every prostate cancer patient need androgen deprivation therapy … and make sure that we treat them with ADT?" … that entire eight weeks of treatment and squeeze it down … 're able to treat things precisely down to millimeter …
-
The oxytocin antagonist cligosiban reduces human prostate contractility: Implications for the treatment of benign prostatic hyperplasia.
28 Apr 2024 18:25 GMT
… patients undergoing prostatectomy due to prostate cancer as well as from … for novel BPH treatment options.
British journal of pharmacology. 2024 Apr … Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia., Drug Discovery Disposition and …
-
In a first, HMC uses nuclear medicine to treat prostate cancer
28 Apr 2024 10:01 GMT
Doha, Qatar: Hamad Medical Corporation (HMC) has started using a nuclear medicine treatment technology, known as Lutetium-177 for prostate cancer patients for the first time in Qatar. The first patient successfully received treatment at HMC’s National …
-
APCCC 2024: How to Deal with the Projected Rise of Prostate Cancer Cases in the Chinese Healthcare System
28 Apr 2024 03:13 GMT
(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a session on global access of advanced prostate cancer in low- and lower-middle income countries, and a presentation by Dr. Dingwei Ye discussing how to deal …
-
APCCC 2024: How to Identify Aggressive Variant Prostate Cancer?
27 Apr 2024 22:19 GMT
… (Alliance) phase 3 trial of neoadjuvant chemohormonal therapy … 150, a phase 3 trial of abiraterone +/ … treatment targets.
What are the PET features of neuroendocrine prostate cancer … prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial …
-
APCCC 2024: Dealing with Inequality – the Promise and Pitfalls for Social Media and AI for Prostate Cancer in Disadvantaged Populations
27 Apr 2024 22:19 GMT
(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a session on global access to advanced prostate cancer in low- and lower-middle income countries, and a presentation by Dr. Stacy Loeb discussing the promise and …
-
APCCC 2024: How Do We Maximize Use of Radiotherapy for Prostate Cancer in Africa
27 Apr 2024 17:20 GMT
(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a session on global access to advanced prostate cancer in low- and lower-middle-income countries, and a presentation by Dr. Omolara Aminat Fatiregun discussing …
-
JnJ gets positive CHMP opinion for Rybrevant, chemotherapy combo for first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
28 Apr 2024 07:55 GMT
… EGFR exon 20 insertion NSCLC treatment landscape, demonstrating significantly improved … , versus chemotherapy alone,” said trial investigator Professor Nicolas Girard, Head … deaths than breast cancer and prostate cancer combined.
The main subtypes of …
-
APCCC 2024: When to Do Tumor Genomic Profiling in Advanced Prostate Cancer and What?
27 Apr 2024 01:53 GMT
… change with subsequent treatments and re-evaluation … of cancer progression for treatment decision-making.” Dr. … may influence treatment decisions – first-line mCRPC treatment, BRCA1, … ProBIO trial assessing genomic re-testing in advanced prostate cancer:
Dr …